Noga Shem-Tov
Overview
Explore the profile of Noga Shem-Tov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kedmi M, Shouval R, Fried S, Bomze D, Fein J, Cohen Z, et al.
Transplant Cell Ther
. 2022 Feb;
28(5):251-257.
PMID: 35218999
Anti CD19 chimeric antigen receptor (CAR) T-cell therapy has transformed the care of relapsed and refractory aggressive B-cell lymphoma. However, financial toxicity and manufacturing time represent barriers to its widespread...
12.
Shem-Tov N, Yerushalmi R, Danylesko I, Litachevsky V, Levy I, Olmer L, et al.
Br J Haematol
. 2021 Oct;
196(4):884-891.
PMID: 34713441
The immunogenicity and safety of Pfizer-BioNTech BNT162b2 mRNA vaccine in allogeneic haematopoietic stem cell transplantation (HSCT) recipients are unknown. We prospectively followed 152 HSCT recipients who were at least six...
13.
Rahav G, Lustig Y, Lavee J, Benjamini O, Magen H, Hod T, et al.
EClinicalMedicine
. 2021 Oct;
41:101158.
PMID: 34693234
Background: Trials of the Pfizer-BioNTech BNT162b2 mRNA vaccine showed 95% efficacy in preventing symptomatic disease; however, the trials excluded immunocompromised patients (ICPs). We aim at analyzing antibody response in ICPs....
14.
Danylesko I, Sareli R, Varda-Bloom N, Yerushalmi R, Shem-Tov N, Magen H, et al.
Int J Hematol
. 2021 Jul;
114(3):363-372.
PMID: 34213732
Autologous stem cell transplantation (ASCT) is a standard of care in newly-diagnosed multiple myeloma (MM) patients. Several studies before the introduction of novel therapies in MM, demonstrated a pegylated G-CSF...
15.
Geva M, Pryce A, Shouval R, Fein J, Danylesko I, Shem-Tov N, et al.
Bone Marrow Transplant
. 2021 Jun;
56(11):2690-2696.
PMID: 34188181
Risk stratification is important for balancing potential risks and benefits of allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies. We retrospectively studied 1119 patients undergoing allogenic-HSCT in a single...
16.
Danylesko I, Canaani J, Shimoni A, Fein J, Shem-Tov N, Yerushalmi R, et al.
Acta Haematol
. 2021 Jun;
144(6):613-619.
PMID: 34102632
Introduction: Achievement of an initial complete remission (CR) following induction chemotherapy is tightly correlated with survival in acute myeloid leukemia (AML) patients, yet patients in CR with incomplete hematologic recovery...
17.
Danylesko I, Shouval R, Shem-Tov N, Yerushalmi R, Jacoby E, Besser M, et al.
Bone Marrow Transplant
. 2020 Dec;
56(5):1134-1143.
PMID: 33268830
We present three patients with aggressive non-Hodgkin's B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed...
18.
Shimoni A, Shem-Tov N, Yerushalmi R, Danylesko I, Nagler A
Bone Marrow Transplant
. 2020 Sep;
56(2):451-456.
PMID: 32873915
Acute graft-versus-host disease (aGVHD) is the major treatment-related complication after stem-cell transplantation (SCT) from unrelated donors. The proteasome-inhibitor bortezomib was added to GVHD prevention regimens with initial promise. However, two...
19.
Canaani J, Nagar M, Heering G, Gefen C, Yerushalmi R, Shem-Tov N, et al.
Oncotarget
. 2020 Jun;
11(23):2233-2245.
PMID: 32577167
A substantial segment of patients with acute myeloid leukemia (AML) will relapse following an initial response to induction therapy or will prove to be primary refractory. High-dose cytarabine and mitoxantrone...
20.
Danylesko I, Jacoby E, Yerushalmi R, Shem-Tov N, Besser M, Vernitsky H, et al.
Leukemia
. 2020 Jan;
34(7):1939-1942.
PMID: 31980731
No abstract available.